Lung Cancer

FDA Grants Sintilimab/Pemetrexed Review for Frontline Nonsquamous NSCLC

May 19, 2021

A biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer has been accepted for FDA review.

Reduce Recurrence in Early-Stage NSCLC

May 05, 2021

Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.